颈动脉粥样硬化易损斑块与血液生物标记物研究进展
Research Progress of Carotid Atherosclerotic Plaques and Blood Biomarkers
DOI: 10.12677/ACM.2023.13102363, PDF,   
作者: 刘毅恒*：青海大学研究生院，青海 西宁；侯 倩#：青海省人民医院神经内科，青海 西宁
关键词: 缺血性脑卒中；颈动脉粥样硬化；易损斑块；生物标记物；Ischemic Stroke； Carotid Atherosclerosis； Vulnerable Plaque； Biomarker
摘要: 动脉粥样硬化是缺血性脑卒中的重要病理基础，其中30%由颈动脉粥样硬化性疾病引起。颈动脉易损斑块破裂、溃疡、血小板活化、血栓形成引起的动脉血栓被认为是缺血性脑卒中的发病机制，所以早期发现和治疗颈动脉易损斑块对缺血性脑卒中有着重大意义，研究表明，除了分子影像技术外，血液生物标记物也可为颈动脉斑块稳定性提供一定的诊断价值。
Abstract: Atherosclerosis is an important pathological basis of ischemic stroke, 30% of which are caused by carotid atherosclerotic diseases. Arterial thrombosis caused by rupture, ulceration, platelet activa-tion and thrombosis of vulnerable carotid plaque are considered to be the pathogenesis of ischemic stroke. Therefore, early detection and treatment of vulnerable carotid plaque are of great signifi-cance for ischemic stroke. Studies have shown that in addition to molecular imaging technology, blood biomarkers can also provide certain diagnostic value for the stability of carotid plaque.
文章引用：刘毅恒, 侯倩. 颈动脉粥样硬化易损斑块与血液生物标记物研究进展[J]. 临床医学进展, 2023, 13(10): 16870-16875. https://doi.org/10.12677/ACM.2023.13102363

参考文献

[1] Tu, W.J., Wang, L.D. and Special Writing Group of China Stroke Surveillance R (2023) China Stroke Surveillance Re-port 2021. Military Medical Research, 10, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[2] Mushenkova, N.V., Summerhill, V.I., Zhang, D., et al. (2020) Current Advances in the Diagnostic Imaging of Atherosclerosis: Insights into the Pathophysiology of Vulnerable Plaque. International Journal of Molecular Sciences, 21, Article No. 2992. [Google Scholar] [CrossRef] [PubMed]
[3] Zhu, Y., Xian, X., Wang, Z., et al. (2018) Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[4] Singh, S.K. and Agrawal, A. (2019) Functionality of C-Reactive Protein for Atheroprotection. Frontiers in Immunology, 10, Article No. 1655. [Google Scholar] [CrossRef] [PubMed]
[5] Sun, H., Koike, T., Ichikawa, T., et al. (2005) C-Reactive Protein in Atherosclerotic Lesions: Its Origin and Pathophysiological Significance. The American Journal of Pathology, 167, 1139-1148. [Google Scholar] [CrossRef] 
[6] Nguyen, M.T., Fernando, S., Schwarz, N., et al. (2019) In-flammation as a Therapeutic Target in Atherosclerosis. Journal of Clinical Medicine, 8, Article No. 1109. [Google Scholar] [CrossRef] [PubMed]
[7] Rose-John, S. (2020) Interleukin-6 Signalling in Health and Disease. F1000Research, 9, 1013. [Google Scholar] [CrossRef] [PubMed]
[8] Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) IL-6 in In-flammation, Immunity, and Disease. Cold Spring Harbor Perspectives in Biology, 6, a016295. [Google Scholar] [CrossRef] [PubMed]
[9] Chen, J., Wang, W., Ni, Q., et al. (2022) Interleukin 6-Regulated Macrophage Polarization Controls Atherosclerosis-Associated Vascular Intimal Hyperplasia. Frontiers in Immunology, 13, Article ID: 952164. [Google Scholar] [CrossRef] [PubMed]
[10] Su, J.H., Luo, M.Y., Liang, N., et al. (2021) Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases. Frontiers in Pharmacology, 12, Article ID: 745061. [Google Scholar] [CrossRef] [PubMed]
[11] Gonzalez, L.L., Garrie, K. and Turner, M.D. (2020) Role of S100 Proteins in Health and Disease. BBA Molecular Cell Research, 1867, Article ID: 118677. [Google Scholar] [CrossRef] [PubMed]
[12] Donato, R., Cannon, B.R., Sorci, G., et al. (2013) Functions of S100 Proteins. Current Molecular Medicine, 13, 24-57. [Google Scholar] [CrossRef] [PubMed]
[13] Zhou, Y., Zha, Y., Yang, Y., et al. (2023) S100 Proteins in Cardiovascular Diseases. Molecular Medicine, 29, Article No. 68. [Google Scholar] [CrossRef] [PubMed]
[14] Croce, K. (2010) S100A8/A9 Complex: More than Just a Bi-omarker of Cardiovascular Risk? Circulation Journal, 74, 626-627. [Google Scholar] [CrossRef] 
[15] Endo, Y., Fujita, M. and Ikewaki, K. (2023) HDL Functions-Current Status and Future Perspectives. Biomolecules, 13, Article No. 105. [Google Scholar] [CrossRef] [PubMed]
[16] Adorni, M.P., Ronda, N., Bernini, F., et al. (2021) High Density Lip-oprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives. Cells, 10, Article No. 574. [Google Scholar] [CrossRef] [PubMed]
[17] Lutjohann, D., Klor, H.U. and Stellaard, F. (2023) Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol as Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations. Nutrients, 15, Article No. 2202. [Google Scholar] [CrossRef] [PubMed]
[18] Wu, Z., Li, X., Wen, Q., et al. (2022) Serum LDL-C/HDL-C Ratio and the Risk of Carotid Plaques: A Longitudinal Study. BMC Cardiovascular Disorders, 22, Article No. 501. [Google Scholar] [CrossRef] [PubMed]
[19] Li, T.D. and Zeng, Z.H. (2018) Adiponec-tin as a Potential Therapeutic Target for the Treatment of Restenosis. Biomedicine & Pharmacotherapy, 101, 798-804. [Google Scholar] [CrossRef] [PubMed]
[20] Choi, H.M., Doss, H.M. and Kim, K.S. (2020) Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. International Journal of Molecular Sciences, 21, Arti-cle No. 1219. [Google Scholar] [CrossRef] [PubMed]
[21] Barseghian, A., Gawande, D. and Bajaj, M. (2011) Adi-ponectin and Vulnerable Atherosclerotic Plaques. Journal of the American College of Cardiology, 57, 761-770. [Google Scholar] [CrossRef] [PubMed]
[22] Denver, R.J., Bonett, R.M. and Boorse, G.C. (2011) Evolution of Leptin Structure and Function. Neuroendocrinology, 94, 21-38. [Google Scholar] [CrossRef] [PubMed]
[23] Katsiki, N., Mikhailidis, D.P. and Banach, M. (2018) Leptin, Cardiovascular Diseases and Type 2 Diabetes Mellitus. Acta Pharma-cologica Sinica, 39, 1176-1188. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, S., Cui, F., Ning, K., et al. (2022) Role of Irisin in Physiology and Pathology. Frontiers in Endocrinology (Lausanne), 13, Article ID: 962968. [Google Scholar] [CrossRef] [PubMed]
[25] Liu, C., Wei, A. and Wang, T. (2022) Irisin, an Effective Treat-ment for Cardiovascular Diseases? Journal of Cardiovascular Development and Disease, 9, Article No. 305. [Google Scholar] [CrossRef] [PubMed]
[26] Byun, K. and Lee, S. (2020) The Potential Role of Irisin in Vascular Function and Atherosclerosis: A Review. International Journal of Molecular Sciences, 21, Article No. 7184. [Google Scholar] [CrossRef] [PubMed]
[27] Wang, X. and Khalil, R.A. (2018) Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Advances in Pharmacology, 81, 241-330. [Google Scholar] [CrossRef] [PubMed]
[28] Florence, J.M., Krupa, A., Booshehri, L.M., et al. (2017) Metal-loproteinase-9 Contributes to Endothelial Dysfunction in Atherosclerosis via Protease Activated Receptor-1. PLOS ONE, 12, e0171427. [Google Scholar] [CrossRef] [PubMed]
[29] Silvello, D., Narvaes, L.B., Albuquerque, L.C., et al. (2014) Serum Levels and Polymorphisms of Matrix Metalloproteinases (MMPs) in Carotid Artery Atherosclerosis: Higher MMP-9 Levels Are Associated with Plaque Vulnerability. Biomarkers, 19, 49-55. [Google Scholar] [CrossRef] 
[30] Lu, T.X. and Rothenberg, M.E. (2018) MicroRNA. Journal of Allergy and Clinical Immunology, 141, 1202-1207. [Google Scholar] [CrossRef] [PubMed]
[31] Lu, Y., Thavarajah, T., Gu, W., et al. (2018) Impact of miRNA in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, e159-e170. [Google Scholar] [CrossRef] 
[32] Laffont, B. and Rayner, K.J. (2017) MicroRNAs in the Pathobiology and Therapy of Atherosclerosis. Canadian Journal of Cardiology, 33, 313-324. [Google Scholar] [CrossRef] [PubMed]

为你推荐